0001209191-17-046030.txt : 20170721
0001209191-17-046030.hdr.sgml : 20170721
20170721200900
ACCESSION NUMBER: 0001209191-17-046030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170719
FILED AS OF DATE: 20170721
DATE AS OF CHANGE: 20170721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SMITH IAN F
CENTRAL INDEX KEY: 0001197032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 17977417
MAIL ADDRESS:
STREET 1: C/O ACORDA THERAPEUTICS, INC.
STREET 2: 420 SAW MILL RIVER ROAD
CITY: ARDSLEY
STATE: NY
ZIP: 10502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-07-19
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001197032
SMITH IAN F
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, CFO & COO
Common Stock
2017-07-19
4
M
0
25500
96.87
A
151738
D
Common Stock
2017-07-19
4
M
0
10775
91.05
A
162513
D
Common Stock
2017-07-19
4
M
0
55250
77.31
A
217763
D
Common Stock
2017-07-19
4
M
0
31875
83.36
A
249638
D
Common Stock
2017-07-19
4
S
0
123400
161.00
D
126238
D
Common Stock
2017-07-21
4
S
0
400
157.56
D
125838
D
Common Stock
2017-07-21
4
S
0
1829
158.62
D
124009
D
Common Stock
2017-07-21
4
S
0
815
159.61
D
123194
D
Common Stock
2017-07-21
4
S
0
2000
161.01
D
121194
D
Common Stock
2017-07-21
4
S
0
5106
161.71
D
116088
D
Common Stock
2017-07-21
4
S
0
200
162.40
D
115888
D
Common Stock
5306
I
401k
Stock Option (Right to Buy)
96.87
2017-07-19
4
M
0
25500
0.00
D
2024-07-14
Common Stock
25500
8500
D
Stock Option (Right to Buy)
91.05
2017-07-19
4
M
0
10775
0.00
D
2026-02-01
Common Stock
10775
23707
D
Stock Option (Right to Buy)
77.31
2017-07-19
4
M
0
55250
0.00
D
2024-02-04
Common Stock
55250
12750
D
Stock Option (Right to Buy)
83.36
2017-07-19
4
M
0
31875
0.00
D
2023-07-29
Common Stock
31875
2125
D
Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $157.56 (range $156.99 to $157.90).
Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $158.62 (range $158.11 to $159.09).
Open market sales reported on this line occurred at a weighted average price of $159.61 (range $159.16 to $159.90).
Open market sales reported on this line occurred at a weighted average price of $161.01 (range $160.28 to $161.24).
Open market sales reported on this line occurred at a weighted average price of $161.71 (range $161.28 to $162.20).
Open market sales reported on this line occurred at a weighted average price of $162.40 (range $162.39 to $162.40).
The option vests in 16 quarterly installments from 7/15/2014.
The option vests in 16 quarterly installments from 02/02/2016.
The option vests in 16 quarterly installments from 02/05/2014.
The option vests in 16 quarterly installments from 07/30/2013.
/s/ Omar White, Attorney-in-Fact
2017-07-21